NASDAQ:OSMT - Osmotica Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.25
  • Forecasted Upside: 55.99 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$5.93
▼ -0.13 (-2.15%)
1 month | 3 months | 12 months
Get New Osmotica Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OSMT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OSMT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$9.25
▲ +55.99% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Osmotica Pharmaceuticals in the last 3 months. The average price target is $9.25, with a high forecast of $12.00 and a low forecast of $4.00. The average price target represents a 55.99% upside from the last price of $5.93.
Buy
The current consensus among 4 polled investment analysts is to buy stock in Osmotica Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/2/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/31/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/29/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/27/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/23/2020

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/3/2020Wells Fargo & CompanyReiterated RatingHoldHigh
i
Rating by Jacob Hughes at Wells Fargo & Company
7/10/2020SunTrust BanksBoost Price TargetBuy$8.00 ➝ $11.00High
i
7/10/2020SVB LeerinkBoost Price TargetOutperform$8.00 ➝ $10.00High
i
Rating by A. Fadia at SVB Leerink LLC
7/9/2020Royal Bank of CanadaBoost Price Target$10.00 ➝ $12.00High
i
3/25/2020Royal Bank of CanadaReiterated RatingBuy$10.00High
i
3/23/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$4.00Low
i
3/18/2020SunTrust BanksInitiated CoverageBuy$8.00High
i
3/6/2020SVB LeerinkInitiated CoverageOutperform$10.00Low
i
Rating by A. Fadia at SVB Leerink LLC
8/12/2019Jefferies Financial GroupSet Price TargetBuy$10.00Medium
i
Rating by David Steinberg at Jefferies Financial Group Inc.
8/9/2019Wells Fargo & CompanyReiterated RatingBuyLow
i
Rating by David Maris at Wells Fargo & Company
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$11.00High
i
3/28/2019Wells Fargo & CompanySet Price TargetBuy$14.00High
i
Rating by David Maris at Wells Fargo & Company
11/14/2018BarclaysInitiated CoverageOverweightHigh
i
11/12/2018Jefferies Financial GroupInitiated CoverageBuy ➝ BuyHigh
i
11/12/2018Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$18.00High
i
11/12/2018Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$17.00High
i
(Data available from 11/24/2015 forward)
Osmotica Pharmaceuticals logo
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone, a chlorzoxazone scored tablet for muscle spasms; ConZip, a tramadol hydrochloride extended-release capsule to treat pain; and Arbaclofen tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity. It also provides women's health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Read More

Today's Range

Now: $5.93
$5.84
$6.13

50 Day Range

MA: $5.85
$5.13
$6.29

52 Week Range

Now: $5.93
$2.81
$9.67

Volume

159,840 shs

Average Volume

386,789 shs

Market Capitalization

$305.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.27